Influenza Vaccination Recommended for Nearly 85% of Americans

Published in September 24th, 2008

Comments Off

Experts speaking at the National Press Club emphasized the need for awareness that influenza morbidity and mortality are preventable through vaccination among at-risk groups, especially healthcare workers.
Medscape Medical News

Two-Year Massachusetts Registry Results Support Mortality Benefit of DES in AMI

Published in September 24th, 2008

Posted by Medscape Pharmacists Headlines in Drugs and Food Information, Health Information, Pharmaceutical Industry News

Comments Off

Whether the benefits are due to restenosis reduction, the additional months of dual antiplatelet therapy, or other effects of the DES itself are unclear, authors note.
Heartwire

Intrathoracic Impedance Predicts Heart-Failure Events in PARTNERS-HF

Published in September 24th, 2008

Posted by Medscape Pharmacists Headlines in Drugs and Food Information, Health Information, Pharmaceutical Industry News

Comments Off

Fluid indices crossing a predefined threshold significantly increased the risk of subsequent heart-failure decompensation, shortness of breath, peripheral edema, and fatigue, suggesting impedance data can help stratify patients at risk for worsening heart failure, report investigators.
Heartwire

ECASS 3: Thrombolysis Beneficial Up to 4.5 Hours After Acute Ischemic Stroke

Published in September 24th, 2008

Posted by Medscape Pharmacists Headlines in Drugs and Food Information, Health Information, Pharmaceutical Industry News

Comments Off

Results of the randomized ECASS 3 trial confirm a “modest but significant” benefit from thrombolytic therapy given up to 4.5 hours after stroke onset, but the authors emphasize that early treatment is still the goal.
Medscape Medical News

FDA Safety Changes: Reclast, Celestone Soluspan, Cymbalta

Published in September 24th, 2008

Posted by Medscape Pharmacists Headlines in Drugs and Food Information, Health Information, Pharmaceutical Industry News

Comments Off

The FDA has approved revisions to the safety labeling for zoledronic acid infusion, betamethasone acetate plus betamethasone sodium phosphate injection, and duloxetine delayed-release capsules.
Medscape Medical News

Inhaled Anticholinergics for COPD Raise CV Event Risk in Meta-Analysis

Published in September 24th, 2008

Posted by Medscape Pharmacists Headlines in Drugs and Food Information, Health Information, Pharmaceutical Industry News

Comments Off

In a meta-analysis, long-term use of inhaled ipratropium or tiotropium bromide in patients with chronic obstructive pulmonary disease independently increased the risk for cardiovascular death by 80%.
Medscape Medical News

Single-Day Famciclovir May Be as Effective as 3-Day Valacyclovir for Genital Herpes

Published in September 24th, 2008

Posted by Medscape Pharmacists Headlines in Drugs and Food Information, Health Information, Pharmaceutical Industry News

Comments Off

In a randomized, double-blind, comparative trial, single-day famciclovir (1000 mg twice daily) was as effective as 3-day valacyclovir (500 mg twice daily) for treating genital herpes.
Medscape Medical News

FDA Safety Changes: Reclast, Celestone Soluspan, Cymbalta

Published in September 24th, 2008

Posted by Medscape Pharmacists Headlines in Drugs and Food Information, Health Information, Pharmaceutical Industry News

Comments Off

The FDA has approved revisions to the safety labeling for zoledronic acid infusion, betamethasone acetate plus betamethasone sodium phosphate injection, and duloxetine delayed-release capsules.
Medscape Medical News

Inhaled Anticholinergics for COPD Raise CV Event Risk in Meta-Analysis

Published in September 24th, 2008

Posted by Medscape Pharmacists Headlines in Drugs and Food Information, Health Information, Pharmaceutical Industry News

Comments Off

In a meta-analysis, long-term use of inhaled ipratropium or tiotropium bromide in patients with chronic obstructive pulmonary disease independently increased the risk for cardiovascular death by 80%.
Medscape Medical News

Single-Day Famciclovir May Be as Effective as 3-Day Valacyclovir for Genital Herpes

Published in September 24th, 2008

Posted by Medscape Pharmacists Headlines in Drugs and Food Information, Health Information, Pharmaceutical Industry News

Comments Off

In a randomized, double-blind, comparative trial, single-day famciclovir (1000 mg twice daily) was as effective as 3-day valacyclovir (500 mg twice daily) for treating genital herpes.
Medscape Medical News